TY - JOUR
T1 - Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2)
T2 - I-move multicentre case control studies at primary care and hospital levels in Europe
AU - I-MOVE/I-MOVE+ study team
AU - Kissling, E.
AU - Rondy, M.
AU - Kaić, Bernard
AU - Horváth, Judit Kriszttina
AU - Ferenczi, Annmária
AU - Oroszi, Beatrix
AU - Vizler, Zita
AU - Hercegh, Éva
AU - Szala, Bálin
AU - Alfonsi, Valeria
AU - Bella, Antonino
AU - Paradowska-Stankiewicz, Iwona
AU - Brydak, Lidia
AU - Nunes, Baltazar
AU - Machado, Ausenda
AU - Rodrigues, Ana Paula
AU - Gomez, Verónica
AU - Kislaya, Irina
AU - Uva, Mafalda Sousa
AU - Guiomar, Raquel
AU - Pechirra, Pedro
AU - Cristóvao, Paula
AU - Conde, Patrícia
AU - Costa, Ines
AU - Pitigoi, Daniela
AU - Lupulescu, Emilia
AU - Ivanciuc, Alina Elena
AU - Lazar, Mihaela
AU - Cherciu, Carmen Maria
AU - Larrauri, Amparo
AU - Gherasim, Alin
AU - Pozo, Francisco
AU - Comas, Luis García
AU - Carril, Fernando Gonzalez
AU - Castilla, Jesus
AU - Quinones, Carmen
AU - Giménez, Jaume
AU - Castrillejo, Daniel
AU - Amores, Madalen Oribe
AU - Falchi, Alessandra
AU - Vilcu, Ana Maria
AU - Souty, Cécile
AU - Blanchon, Thierry
AU - Behillil, Sylvie
AU - Enouf, Vincent
AU - Cité, Sornonne Paris
AU - Lina, Bruno
AU - Valette, Martine
AU - Reuss, Anicka
AU - Buda, Silke
PY - 2017/2/16
Y1 - 2017/2/16
N2 - We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65-79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
AB - We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65-79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
UR - http://www.scopus.com/inward/record.url?scp=85014105621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014105621&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2017.22.7.30464
DO - 10.2807/1560-7917.ES.2017.22.7.30464
M3 - Article
C2 - 28230524
AN - SCOPUS:85014105621
VL - 22
JO - Eurosurveillance
JF - Eurosurveillance
SN - 1560-7917
IS - 7
ER -